Southern Firm (NYSE:SO) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -1.03% to $50.96. Southern commences (SO) reported that 32.5 million ordinary stock offering for predictable gross proceeds of $1.6 billion; implying offering price at $49.24/share. The net proceeds from the offering will be used to fund a portion of the purchase price for the pending purchase of a 50% equity interest in Southern Natural Gas and for other general corporate purposes, which may include the investment by the firm in its subsidiaries, comprising Southern Power. The share price of SO attracts active investors, as stock price of week volatility recorded 1.05%. The stock is going forward to its 52-week low with 27.50% and lagging behind from its 52-week high price with -5.74%.
OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) [Trend Analysis] moved down reacts as active mover, shares a decrease -41.08% to traded at $0.53 and the percentage gap among open changing to regular change was -36.65%. OncoGenex Pharmaceuticals, Inc. (OGXI) reported that results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed following treatment with docetaxel.
The trial did not meet the primary endpoint of demonstrating a statistically important improvement in overall survival for patients treated with custirsen in combination with cabazitaxel/prednisone compared to cabazitaxel/prednisone alone. The adverse events were consistent with those observed in previous trials of custirsen in metastatic CRPC.
The final data will be submitted as a late-breaking abstract to the European Society for Medical Oncology (ESMO) Yearly Congress 2016. “We are obviously disdesignated that custirsen was unable to demonstrate a survival benefit in prostate cancer. We would like to thank the patients who take partd in the AFFINITY trial and their caregivers, as well as the investigators and their teams for their commitment to improving cancer care for patients who are in desperate need of new treatment options,” stated Scott Cormack , President and CEO of OncoGenex. The firm’s current ratio calculated as 3.00 for the most recent quarter. The firm past twelve months price to sales ratio was 0.90 and price to cash ratio remained 0.40. As far as the returns are concern, the return on equity was recorded as -48.70%, while its return on asset stayed at -31.00%. The firm has total debt to equity ratio measured as 0.01.
General Electric Firm (NYSE:GE) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.16% to close at $31.19 with the total traded volume of 22.36 Million shares. The CEO of the General Electric (GE)’s gas power systems business, Joe Mastrangelo stated that the firm’s recent $250 million accord with Korea’s Doosan Engineering and Construction could boost incomes from its $9.5 billion purchase of Alstom (ALSMY) power assets previous year. GE purchased Doosan’s heat recovery steam generator earlier this year.
The unit offers critical engineering and manufacturing capacity that the firm needs as its Alstom sales raise, according to Reuters. Mastrangelo told Reuters that the firm added 30 orders for heat recovery system generators since the Astrom accord closed previous year. Typically the firm sold 14 yearlyly previous to the acquisition. The firm has institutional ownership of 58.60%, while insider ownership included 0.05%. Its price to sales ratio ended at 2.38. GE attains analyst recommendation of 2.30 with week performance of -0.35%.